Willow Biosciences Inc
OTC:CANSF
Balance Sheet
Balance Sheet Decomposition
Willow Biosciences Inc
Willow Biosciences Inc
Balance Sheet
Willow Biosciences Inc
| Jun-2013 | Jun-2014 | Jun-2015 | Jun-2016 | Jun-2017 | Jun-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
20
|
16
|
30
|
11
|
3
|
0
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
20
|
16
|
30
|
11
|
3
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
|
| Total Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
21
|
17
|
31
|
16
|
4
|
1
|
|
| PP&E Net |
2
|
2
|
2
|
2
|
2
|
0
|
7
|
5
|
4
|
2
|
2
|
2
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
7
|
5
|
4
|
2
|
2
|
2
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
5
|
8
|
11
|
7
|
8
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
6
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
2
N/A
|
2
+12%
|
2
+2%
|
2
0%
|
2
-30%
|
1
-58%
|
34
+4 606%
|
22
-35%
|
35
+60%
|
18
-48%
|
7
-63%
|
2
-63%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
1
|
2
|
2
|
2
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
10
|
21
|
4
|
0
|
0
|
0
|
|
| Total Liabilities |
1
N/A
|
1
-23%
|
1
+11%
|
1
+34%
|
2
+48%
|
1
-58%
|
12
+1 264%
|
22
+89%
|
5
-76%
|
2
-67%
|
3
+83%
|
3
-8%
|
|
| Equity | |||||||||||||
| Common Stock |
16
|
17
|
18
|
19
|
20
|
22
|
73
|
83
|
118
|
118
|
118
|
121
|
|
| Retained Earnings |
15
|
16
|
17
|
18
|
20
|
22
|
54
|
88
|
94
|
109
|
122
|
128
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
4
|
6
|
7
|
7
|
7
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
1
N/A
|
1
+60%
|
1
-4%
|
1
-27%
|
0
N/A
|
0
+61%
|
22
N/A
|
1
N/A
|
30
N/A
|
16
-45%
|
3
-79%
|
1
N/A
|
|
| Total Liabilities & Equity |
2
N/A
|
2
+12%
|
2
+2%
|
2
0%
|
2
-30%
|
1
-58%
|
34
+4 606%
|
22
-35%
|
35
+60%
|
18
-48%
|
7
-63%
|
2
-63%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
1
|
0
|
0
|
16
|
19
|
25
|
25
|
25
|
29
|
|